Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioCryst Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding BioCryst Pharmaceuticals Inc’s stock price such as:

• BioCryst Pharmaceuticals Inc’s current stock price and volume
• Why BioCryst Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for BCRX from analysts
• BCRX’s stock price momentum as measured by its relative strength

About BioCryst Pharmaceuticals Inc (BCRX)

Before we jump into BioCryst Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Want to learn more about BioCryst Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioCryst Pharmaceuticals Inc.

What Caused BioCryst Pharmaceuticals Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 28, 2024, there were 6 analysts who downgraded BioCryst Pharmaceuticals Inc’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BioCryst Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioCryst Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioCryst Pharmaceuticals Inc (BCRX) by visiting AAII Stock Evaluator.

Relative Price Strength of BioCryst Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 28, 2024, BioCryst Pharmaceuticals Inc has a weighted four-quarter relative price strength of -1.51%, which translates to a Momentum Score of 67 and is considered to be Strong.

Want to learn more about how BioCryst Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioCryst Pharmaceuticals Inc Stock Price: Bottom Line

As of July 1, 2024, BioCryst Pharmaceuticals Inc’s stock price is $6.67, which is up 7.93% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioCryst Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.